查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950014

醫療設備病毒去活化檢測市場：按技術、檢測類型、設定、樣本類型、應用和最終用戶分類－全球預測，2026-2032年

Medical Device Viral Inactivation Testing Market by Technology, Testing Type, Setting, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年醫療設備病毒去活化檢測市場價值為 2.0744 億美元，預計到 2026 年將成長至 2.3032 億美元，預計到 2032 年將達到 4.6068 億美元，複合年成長率為 12.07%。

關鍵市場統計數據
基準年 2025 2.0744億美元
預計年份：2026年 2.3032億美元
預測年份 2032 4.6068億美元
複合年成長率 (%) 12.07%

本文簡要概述了病毒去活化檢測對臨床檢查室、生產商和研究實驗室不斷變化的優先事項和戰略意義。

病毒去活化檢測領域正經歷快速變化，這主要受到公共衛生優先事項、生物製造需求和診斷複雜性的共同影響。本執行摘要探討了當前影響該領域的核心主題，包括技術多樣化、診斷和生產流程的整合以及監管作用的日益增強。報告重點闡述了檢測方法如何與臨床、研究和工業環境中的應用需求和操作限制相匹配。

技術多元化和監管重點如何重塑病毒去活化檢測生態系統中的採購、驗證方法和營運協作

過去幾年，受技術成熟、需求多元化和監管趨嚴的驅動，病毒去活化檢測生態系統發生了變革性變化。首先，檢驗的方法組合已從傳統的加熱和化學方法擴展到先進的過濾系統和靶向紫外線照射平台，每種方法都旨在應對不同的風險、通量和基質相容性要求。這種多元化使得通訊協定能夠根據具體應用進行客製化，從即時檢測檢體處理到大規模疫苗生產均可適用。

評估2025年關稅調整如何改變了測試和生產相關人員的供應鏈韌性、籌資策略和營運決策。

2025年前後實施的累積關稅調整對病毒去活化檢測供應鏈產生了顯著影響。進口零件、設備和某些化學試劑的關稅調整增加了許多依賴全球採購的實驗室和製造商的現場成本。這些成本波動迫使採購團隊重新評估供應商集中度、前置作業時間緩衝以及資本設備和持續耗材的總擁有成本 (TCO)。

綜合細分分析揭示了技術選擇、應用需求、最終用戶需求、檢體方法和運行環境如何決定去活化策略的選擇。

詳細的細分分析揭示了技術、應用、最終用戶、樣品類型、檢測方法和操作環境如何造成不同的需求和採用模式。化學去活化、過濾、熱處理和紫外線C波段照射等技術各自具有不同的風險特徵和基質相容性。化學方法具有柔軟性，可適應各種樣品類型；過濾提供適用於液體基質的物理去除方法；熱處理是一種成熟的頻譜方法，可在受控環境下進行；紫外線C波段照射提供了一種非化學去活化方法，對於需要最大限度減少殘留物的流程來說極具吸引力。這些技術的選擇取決於下游分析的靈敏度要求以及所處理生物材料的性質。

區域比較分析：採購重點、監管協調與生產概況如何影響病毒去活化檢測解決方案的採用

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的採購、監管預期和應用路徑。在美洲，臨床檢查室和製造商致力於在保持快速診斷和生產擴張彈性的同時，協調遵守各國法規結構。該地區也在推行區域籌資策略，以降低貿易相關的成本波動，並強調快速部署以及與現有實驗室資訊系統的互通性。

現有企業、專業技術供應商和服務實驗室透過驗證協助、整合工作流程和本地服務能力來脫穎而出。

病毒去活化檢測領域的競爭格局呈現出多元化的特點，既有成熟的生命科學儀器供應商，也有擁有單一檢測平台的專業廠商，還有提供端到端驗證服務的綜合服務實驗室。成熟的儀器製造商利用其廣泛的分銷網路和檢驗的工程及服務基礎設施，服務於大規模醫院系統和製造商；而專業廠商則專注於技術差異化，例如最佳化的UV-C照射系統或針對特定基質設計的新型過濾介質。

為檢查室和生產領導者提供可操作的策略重點，以加強供應鏈韌性、驗證工作流程和營運準備，從而實現持續的測試效能。

產業領導者應採取多管齊下的策略，全面應對營運韌性、驗證嚴謹性和客戶支援等問題。首先，應實現供應商關係多元化，考慮區域採購和本地組裝，以降低關稅波動帶來的成本風險並縮短前置作業時間。其次，應投資模組化驗證框架和數位化記錄系統，以加快不同地點間的方法轉移，並支援符合監管檢查要求的統一文件。

本研究採用綜合性的混合方法研究設計，結合相關人員訪談、技術文獻綜述和情境分析，旨在檢驗營運洞察與採購啟示。

本研究採用混合方法，結合關鍵相關人員訪談、專家諮詢和二手技術文獻回顧，全面了解病毒去活化檢測的現況。主要資訊來源包括與臨床、研究和生產環境中的實驗室主任、品質保證人員、採購專業人員和技術營運經理進行的結構化討論。這些討論重點關注操作限制、技術在實際環境中的性能以及檢驗要求。

策略需求綜合分析強調檢驗、互通性和供應商韌性是病毒去活化測試中持續營運績效的決定因素。

總之，病毒去活化檢測已成為臨床檢查室、研究實驗室和製造商業務決策的核心。為滿足特定樣本基質和通量需求，技術選擇日趨多樣化，而日益成長的監管和採購壓力也使得可靠的驗證、數位化記錄和供應商韌性變得更加重要。在貿易政策不斷變化和品質要求日益提高的環境下，那些積極主動地將技術選擇與應用需求相匹配，並投資於跨職能檢驗能力的組織，將更有利於實現營運連續性和降低風險。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章醫療設備病毒去活化檢測市場（依技術分類）

  • 化學
  • 過濾
  • 熱處理
  • 紫外線（UV-C）照射

第9章 依檢測方法分類的醫療設備病毒去活化檢測市場

  • 定性
  • 定量

第10章 按安裝位置分類的醫療設備病毒去活化測試市場

  • 實驗室
  • 照護端

第11章 依檢體類型分類的醫療設備病毒去活化檢測市場

  • 血液樣本
  • 環境樣品
  • 組織樣本

第12章醫療設備病毒去活化檢測市場（依應用領域分類）

  • 診斷測試
    • 醫院檢查室
    • 即時檢測
  • 研究用途
  • 消毒服務
  • 疫苗生產
    • 去活化疫苗
    • 減毒活病毒疫苗
    • 重組疫苗

第13章醫療設備病毒去活化檢測市場（依最終用戶分類）

  • 診斷中心
  • 醫院和診所
  • 製藥公司
  • 研究所

第14章醫療設備病毒去活化檢測市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章醫療設備病毒去活化檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國醫療設備病毒去活化檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國醫療設備病毒去活化檢測市場

第18章：中國醫療設備病毒去活化檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bertin Technologies
  • BioMrieux
  • Charles River Laboratories
  • Ecovadis
  • Lonza
  • MedDevice
  • Merck KGaA
  • Pall Corporation
  • SGS
  • Sterigenics
  • The Biovac Initiative
  • Thermo Fisher Scientific
  • ViroStat
  • WuXi AppTec
Product Code: MRR-4F7A6D4FBA02

The Medical Device Viral Inactivation Testing Market was valued at USD 207.44 million in 2025 and is projected to grow to USD 230.32 million in 2026, with a CAGR of 12.07%, reaching USD 460.68 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 207.44 million
Estimated Year [2026] USD 230.32 million
Forecast Year [2032] USD 460.68 million
CAGR (%) 12.07%

Concise orientation to the evolving priorities and strategic implications of viral inactivation testing for clinical laboratories, manufacturers, and research institutions

The landscape for viral inactivation testing is evolving rapidly as public health priorities, biomanufacturing demands, and diagnostic complexity converge. This executive summary introduces the core themes that shape the discipline today, including technological diversification, integration across diagnostic and production workflows, and the heightened role of regulatory oversight. It places particular emphasis on how testing modalities align with application needs and operational constraints in clinical, research, and industrial settings.

As organizations work to maintain biosafety and product integrity, viral inactivation testing has shifted from a compliance-driven checkbox to a strategic capability. Laboratories and manufacturers must align method selection with sample matrix characteristics, turnaround expectations, and downstream use cases. The introduction frames subsequent sections by laying out the transformational shifts in delivery models, the trade environment implications for 2025, and segmentation and regional perspectives that decision-makers need to prioritize when planning investments in equipment, consumables, and technical expertise.

How technological diversification and regulatory emphasis are reshaping procurement, validation practices, and operational collaboration across the viral inactivation testing ecosystem

Over the past several years, the viral inactivation testing ecosystem has experienced transformative shifts driven by technological maturation, demand-side diversification, and regulatory tightening. First, the portfolio of validated approaches has broadened beyond traditional heat and chemical methods to include advanced filtration systems and targeted UV-C irradiation platforms, each designed to meet different risk, throughput, and matrix compatibility profiles. This diversification is enabling practitioners to tailor protocols to specific applications, from point-of-care specimen handling to large-scale vaccine production.

Second, adoption patterns have changed as diagnostic testing moved closer to the patient and as vaccine manufacturing scaled to meet global needs. Point-of-care settings increasingly require rapid, reliable inactivation steps that preserve diagnostic targets, while production environments prioritize high-throughput methods that maintain antigenic integrity for downstream formulation. Concurrently, cross-functional collaboration between quality assurance, regulatory affairs, and laboratory operations has become more pronounced, because validation requirements now extend to process controls, traceability, and documentation spanning the whole lifecycle of a test or product.

Third, data-centric validation and digital recordkeeping are growing in importance. Laboratories and manufacturers are integrating automated logging, instrument connectivity, and auditable workflows to meet both internal quality goals and external regulatory scrutiny. Taken together, these shifts are reshaping procurement decisions, staffing profiles, and the competitive landscape for providers of instruments, consumables, and validation services.

Assessment of how 2025 tariff adjustments have altered supply chain resilience, procurement strategies, and operational decisions across testing and production stakeholders

The cumulative impact of tariff changes enacted in and around 2025 has introduced material implications for supply chains supporting viral inactivation testing. Tariff adjustments on imported components, instrumentation, and certain chemical reagents have increased landed costs for many laboratories and manufacturers that rely on global sourcing. These cost dynamics have forced procurement teams to reassess supplier concentration, lead-time buffers, and the total cost of ownership for capital equipment and recurring consumables.

In response, organizations have pursued several adaptive strategies. Some have diversified supplier portfolios to include regional vendors or alternative component sources to mitigate single-origin exposure. Others have moved toward greater inventory buffering and negotiated longer-term purchase agreements to stabilize pricing. In certain cases, manufacturers of testing platforms have localized assembly or component supply to soften tariff effects and preserve competitive pricing for strategic customers. These shifts have also altered the calculus for warranty and service contracts, as cross-border maintenance and parts replacement now carry additional logistical and cost considerations.

Furthermore, the tariff environment has sharpened the focus on operational efficiency. Process optimization and increased in-house validation capacities have become pragmatic responses to offset pricing pressures. Across the sector, stakeholders are balancing near-term procurement constraints with longer-term choices about supplier relationships, vertical integration, and resilient operational models that maintain continuity of testing and production under shifting trade conditions.

Integrated segmentation analysis revealing how technology choices, application demands, end-user needs, sample matrices, testing approaches, and operational settings determine inactivation strategy selection

A granular segmentation lens clarifies how technology, application, end-user, sample type, testing approach, and operational setting drive distinct needs and adoption patterns. Technologies such as chemical inactivation, filtration, heat treatments, and UV-C irradiation serve different risk profiles and matrix compatibilities: chemical approaches often offer flexibility for diverse sample types, filtration delivers physical removal suitable for fluid matrices, heat is a well-understood broad-spectrum method for controlled environments, and UV-C irradiation provides non-chemical inactivation attractive for workflows requiring minimal residuals. The choice among these technologies depends on downstream analytical sensitivity requirements and the nature of the biological material being processed.

Applications span diagnostic testing, research functions, sterilization services, and vaccine production, each with their own performance and documentation expectations. Diagnostic testing includes hospital laboratory workflows and point-of-care testing, which demand rapid, standardized inactivation that preserves diagnostic targets and supports quick turnaround. Vaccine production requires approaches that protect antigenic structures across inactivated vaccines, live attenuated formulations, and recombinant platforms, where inactivation must be validated extensively to ensure safety without compromising efficacy. Research applications and sterilization services add another dimension, emphasizing protocol flexibility, reproducibility, and compatibility with diverse experimental designs.

End users include diagnostic centers, hospitals and clinics, pharmaceutical companies, and research laboratories, and each setting enforces distinct operational priorities from regulatory compliance and patient safety to batch consistency and experimental rigor. Sample types range from blood and tissue samples to environmental swabs, influencing method selection because matrix effects can markedly alter inactivation kinetics and downstream assay performance. Testing approaches vary between qualitative and quantitative modalities, with qualitative methods focused on presence/absence determinations and quantitative methods providing titers or log-reduction metrics critical for production and validation. Finally, the operational setting-whether lab-based or point-of-care-affects instrument footprint, ease of use, and validation burden, leading organizations to choose solutions that balance accuracy, throughput, and operational practicality.

Regional comparative insights showing how procurement priorities, regulatory harmonization, and manufacturing profiles influence the adoption of viral inactivation testing solutions

Regional dynamics influence procurement, regulatory expectations, and the pathways to adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical laboratories and manufacturers are focused on harmonizing compliance with domestic regulatory frameworks while maintaining agility for rapid diagnostic and production scaling. This region often emphasizes rapid deployment and interoperability with existing laboratory information systems, while also pursuing localized sourcing strategies to mitigate trade-related cost volatility.

In Europe, Middle East & Africa, regulatory harmonization across multiple jurisdictions elevates the importance of standardized validation and high-quality documentation. Stakeholders in this region frequently prioritize solutions that demonstrate cross-border regulatory acceptance and accommodate a broad range of healthcare delivery contexts, from advanced tertiary centers to constrained resource environments. The emphasis on environmental sustainability and energy efficiency also influences technology selection in sterilization and inactivation choices.

Asia-Pacific features both high-volume manufacturing hubs and fast-growing point-of-care networks, which leads to divergent needs within the region. Manufacturers prioritize high-throughput, scalable inactivation methods that integrate with production lines, while emerging healthcare markets emphasize compact, easy-to-use solutions suited to decentralized testing. Across all regions, regional supplier ecosystems, tariff considerations, and local regulatory pathways shape procurement strategies and the rate at which new technologies move from validation to routine use.

How incumbents, niche technology providers, and service laboratories are differentiating through validation support, integrated workflows, and localized service capabilities

Competitive dynamics within the viral inactivation testing space are characterized by a blend of established life-science instrument providers, niche specialists in single-method platforms, and integrated service laboratories offering end-to-end validation. Established instrument manufacturers leverage broad distribution networks, validated engineering, and service infrastructures to serve large hospital systems and manufacturers, while specialized vendors focus on technology differentiation such as optimized UV-C delivery systems or novel filtration media designed for specific matrices.

Service laboratories and validation consultancies play an increasingly strategic role by combining technical protocol development, third-party verification, and operational support that reduces time to compliance. These players often partner with instrument vendors or reagent suppliers to deliver bundled solutions that include method transfer, training, and documentation packages that meet regulatory expectations. Strategic partnerships and co-development arrangements are also common, as platform vendors seek to embed consumable pipelines and locked-in consumable ecosystems that enhance customer retention.

Across the competitive field, differentiation is achieved through demonstrable validation data, user-friendly workflow integration, robust service networks, and documented compliance with relevant standards. Vendors that can offer scalable solutions across laboratory and production settings, along with flexible commercial terms and localized support, are best positioned to capture attention from both clinical and industrial buyers. Ultimately, the ability to link technical performance with operational savings and regulatory readiness is the most persuasive value proposition in this space.

Actionable strategic priorities for laboratory and manufacturing leaders to enhance supply chain resilience, validation workflows, and operational readiness for sustained testing performance

Industry leaders should pursue a multi-pronged strategy that addresses operational resilience, validation rigor, and customer enablement. First, diversify supplier relationships and explore regionalized sourcing or localized assembly to reduce exposure to tariff-driven cost fluctuations and to shorten lead times. Second, invest in modular validation frameworks and digital recordkeeping that accelerate method transfer between sites and support harmonized documentation suitable for regulatory inspection.

Third, prioritize solutions that demonstrate matrix compatibility across blood, tissue, and environmental samples so that a single platform can address multiple use cases, reducing complexity and total implementation burden. Fourth, strengthen partnerships between quality, regulatory, and laboratory functions to ensure that inactivation protocols are selected and validated with both scientific rigor and operational practicality in mind. This cross-functional alignment helps avoid rework and supports quicker adoption.

Fifth, consider service-based models or vendor partnerships that include method development and ongoing verification services to lower internal burden and to accelerate access to validated workflows. Finally, build internal capability for continuous process improvement so that incremental gains in throughput, reagent usage, and documentation quality compound over time and offset procurement pressures. By combining supply chain resilience, validation excellence, and customer-centric service models, leaders can sustain uninterrupted testing and production while maintaining regulatory compliance and cost discipline.

Comprehensive mixed-methods research design combining stakeholder interviews, technical literature synthesis, and scenario analysis to validate operational insights and procurement impacts

This research adopts a mixed-methods approach combining primary stakeholder interviews, expert consultations, and secondary technical literature appraisal to construct a comprehensive view of the viral inactivation testing landscape. Primary inputs included structured discussions with laboratory directors, quality assurance leads, procurement specialists, and technical operations managers across clinical, research, and manufacturing settings. These conversations focused on operational constraints, technology performance in real-world matrices, and validation requirements.

Secondary analysis drew on peer-reviewed publications, regulatory guidance documents, and manufacturer technical dossiers to cross-validate performance claims, method compatibilities, and documented validation endpoints. Where applicable, white papers and technical application notes were synthesized to clarify instrument operating ranges, consumable lifecycles, and compatibility with diagnostic assays and production workflows. Triangulation across data streams ensured that conclusions reflect both empirical evidence and observed practitioner behavior.

The methodology also incorporated scenario analysis to assess supply chain and tariff impacts, using representative case studies to illustrate procurement responses and resilience strategies. Throughout, emphasis was placed on transparency in data provenance and on clearly documenting methodological assumptions so that readers can interpret findings within their own operational and regulatory contexts.

Synthesis of strategic imperatives emphasizing validation, interoperability, and supplier resilience as the determinants of sustained operational performance in viral inactivation testing

In conclusion, viral inactivation testing has moved to the center of operational decision-making for clinical laboratories, research institutions, and manufacturers. Technological options have diversified to meet specific matrix and throughput needs, while regulatory and procurement pressures have elevated the importance of robust validation, digital recordkeeping, and supplier resilience. Organizations that proactively align technology selection with application requirements and that invest in cross-functional validation capacity will be better positioned to sustain operations and reduce risk in an environment of shifting trade policies and rising quality expectations.

Looking forward, leaders should expect continued emphasis on interoperability, demonstrable validation data, and flexible service models that reduce internal burden. By focusing on modular approaches that can be adapted across settings and by strengthening supplier and operational resilience, stakeholders can ensure continuity of testing and production while preserving scientific integrity and regulatory compliance. The strategic choices made today about platform selection, supplier relationships, and validation approaches will determine the agility and reliability of viral inactivation capabilities for years to come.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medical Device Viral Inactivation Testing Market, by Technology

  • 8.1. Chemical
  • 8.2. Filtration
  • 8.3. Heat
  • 8.4. Uv C Irradiation

9. Medical Device Viral Inactivation Testing Market, by Testing Type

  • 9.1. Qualitative
  • 9.2. Quantitative

10. Medical Device Viral Inactivation Testing Market, by Setting

  • 10.1. Lab Based
  • 10.2. Point Of Care

11. Medical Device Viral Inactivation Testing Market, by Sample Type

  • 11.1. Blood Samples
  • 11.2. Environmental Samples
  • 11.3. Tissue Samples

12. Medical Device Viral Inactivation Testing Market, by Application

  • 12.1. Diagnostic Testing
    • 12.1.1. Hospital Laboratories
    • 12.1.2. Point Of Care Testing
  • 12.2. Research Applications
  • 12.3. Sterilization Services
  • 12.4. Vaccine Production
    • 12.4.1. Inactivated Vaccines
    • 12.4.2. Live Attenuated Vaccines
    • 12.4.3. Recombinant Vaccines

13. Medical Device Viral Inactivation Testing Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Hospitals And Clinics
  • 13.3. Pharmaceutical Companies
  • 13.4. Research Laboratories

14. Medical Device Viral Inactivation Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Medical Device Viral Inactivation Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Medical Device Viral Inactivation Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Medical Device Viral Inactivation Testing Market

18. China Medical Device Viral Inactivation Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bertin Technologies
  • 19.6. BioMrieux
  • 19.7. Charles River Laboratories
  • 19.8. Ecovadis
  • 19.9. Lonza
  • 19.10. MedDevice
  • 19.11. Merck KGaA
  • 19.12. Pall Corporation
  • 19.13. SGS
  • 19.14. Sterigenics
  • 19.15. The Biovac Initiative
  • 19.16. Thermo Fisher Scientific
  • 19.17. ViroStat
  • 19.18. WuXi AppTec

LIST OF FIGURES

  • FIGURE 1. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY CHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY CHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY CHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HEAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HEAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HEAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY UV C IRRADIATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY UV C IRRADIATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY UV C IRRADIATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LAB BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LAB BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LAB BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY STERILIZATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY STERILIZATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY STERILIZATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 169. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 172. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 196. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 199. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 205. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 208. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)